Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | LTA4H | P09960 | 5/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2331145 | 0.75 | CHRNA7 (0.39) | — | |
| Hydrochloric Acid SCHEMBL29089950 | 0.74 | ATP4A (0.40) | HRH3 | |
| SCHEMBL28359252 | 0.72 | KMT2A (0.41) | HRH3LTA4HESR1ESR2ACHE | |
| SCHEMBL5050049 | 0.68 | — | — | |
| SCHEMBL28459014 | 0.68 | — | — | |
| SCHEMBL14970484 | 0.67 | LTA4H (0.97) | HRH3LTA4HPSMB1PSMB5HRH1 | |
| SCHEMBL28587239 | 0.66 | ENPP2 (0.32) | — | |
| SCHEMBL1986256 | 0.66 | PSMB1 (0.70) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL4416554 | 0.66 | PSMB1 (0.70) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL1778223 | 0.66 | PSMB1 (0.70) | HRH3LTA4HPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288528-B2 | Meso-substituted porphyrins | L. Molteni & C. Dei Fratelli Alitti—Società di Esercizio S.p.A. (IT) | 2012-10-16 | — | — | US | claimed |
| EP-1558616-B2 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2011-08-24 | — | — | EP | claimed |
| JP-4751068-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| US-7947674-B2 | Meso-substituted porphyrins | L. Molteni & C. Dei Fratelli Alitti (IT) | 2011-05-24 | — | — | US | claimed |
| US-20110112464-A1 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 2011-05-12 | — | — | US | claimed |
| EP-1558616-B1 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2008-02-27 | — | — | EP | claimed |
| US-20060040914-A1 | Meso-substituted porphyrins | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 2006-02-23 | — | — | US | claimed |
| EP-1558616-A2 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI (IT) | 2005-08-03 | — | — | EP | claimed |
| WO-2004035590-A2 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A (IT) | 2004-04-29 | — | — | WO | claimed |
| US-8288528-B2 | Meso-substituted porphyrins | L. Molteni & C. Dei Fratelli Alitti—Società di Esercizio S.p.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| EP-1558616-B2 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2011-08-24 | — | — | EP | disclosed |
| US-7947674-B2 | Meso-substituted porphyrins | L. Molteni & C. Dei Fratelli Alitti (IT) | 2011-05-24 | — | — | US | disclosed |
| US-20110112464-A1 | MESO-SUBSTITUTED PORPHYRINS | L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA DI ESERCIZIO S.P.A. (IT) | 2011-05-12 | — | — | US | disclosed |
| EP-1558616-B1 | MESO-SUBSTITUTED PORPHYRINS | MOLTENI & C (IT) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040914-A1 | Meso-substituted porphyrins | PPOX, PPIF, ALAD | HRH3 3883/4885LTA4H 4504/4885PSMB1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.